HCA Healthcare, Inc. (NYSE:HCA) is one of the 10 Most Undervalued American Stocks to Invest In.
On June 29, 2026, HCA Healthcare, Inc. (NYSE:HCA) announced new research published in The New England Journal of Medicine showing promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia
The study evaluated exa-cel, a CRISPR-based cell therapy currently approved by the U.S. Food and Drug Administration for eligible patients ages 12 and older with sickle cell disease and transfusion-dependent beta thalassemia. Among participants followed long enough to evaluate the primary endpoints, all eight children with beta thalassemia achieved transfusion independence for at least 12 months, while all eight children with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months.
On June 22, TD Cowen analyst Ryan Langston lowered the firm’s price target on HCA Healthcare to $431 from $500 and kept a Buy rating. Langston reduced TD Cowen’s 2026 and 2027 growth assumptions after its May hospital survey showed flat year-over-year revenue. Survey commentary pointed to weaker surgical volumes that were partially offset by growth in medical volumes.